Coloplast is a global leader in specialized intimate healthcare, with strong innovation, high margins, and a defensible moat in core segments. Despite a 20% share price drop, I see upside potential, ...
There’s something fishy about Coloplast’s latest megadeal—literally. The Danish medtech announced (PDF) plans on Friday to acquire Kerecis, which uses fish skin as the basis of its wound care products ...
Coloplast's stock price has declined by 25% since April 2023, making it more attractive but still overvalued based on fundamentals and valuation multiples. Recent quarterly results show revenue growth ...
The Power Purchase Agreement (PPA) will contribute directly to the construction of a new large solar park and cover 100% of Coloplast’s electricity consumption in Denmark from 2023 onwards. Coloplast ...
Notice of Annual General Meeting 2025 The Annual General Meeting of Coloplast A/S will be held on Thursday, 4 December 2025 ...
Coloplast interim CEO Lars Rasmussen has today informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, ...
Coloplast's wound-care portfolio is relatively limited, especially when compared with the breadth of products from Smith & Nephew, and ConvaTec, which includes high-tech solutions such as ...
COPENHAGEN, July 7 (Reuters) - Coloplast (COLOb.CO), opens new tab has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up ...
Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...
Full year financial results. 1 October 2024 - 30 September 2025. Coloplast delivered Q4 organic growth of 7% and an EBIT margin 1 of 28%. Reported revenue in DKK grew 0% w ...
9monon MSN
Coloplast targets 8%-9% organic growth for FY 2025 amid Kerecis expansion and new launches
Earnings Call Insights: Coloplast A/S (OTCPK:CLPBF) Q1 2025 CEO Kristian Villumsen highlighted 8% organic growth and a ...
COPENHAGEN, Nov 8 (Reuters) - Shares in Coloplast (COLOb.CO), opens new tab rose on Monday after the medical equipment maker said it had agreed a 2.16 billion euros ($2.49 billion) deal to buy Atos ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback